During the last session, Trevi Therapeutics Inc (NASDAQ:TRVI)’s traded shares were 0.4 million, with the beta value of the company hitting 0.88. At the end of the trading day, the stock’s price was $3.91, reflecting an intraday loss of -2.01% or -$0.08. The 52-week high for the TRVI share is $4.68, that puts it down -19.69 from that peak though still a striking 66.5% gain since the share price plummeted to a 52-week low of $1.31. The company’s market capitalization is $349.42M, and the average intraday trading volume over the past 10 days was 0.47 million shares, and the average trade volume was 1.74 million shares over the past three months.
Trevi Therapeutics Inc (TRVI) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.10. TRVI has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.12.
Trevi Therapeutics Inc (NASDAQ:TRVI) trade information
Trevi Therapeutics Inc (TRVI) registered a -2.01% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -2.01% in intraday trading to $3.91, hitting a weekly high. The stock’s 5-day price performance is 3.44%, and it has moved by -3.46% in 30 days. Based on these gigs, the overall price performance for the year is 189.63%. The short interest in Trevi Therapeutics Inc (NASDAQ:TRVI) is 3.87 million shares and it means that shorts have 0.95 day(s) to cover.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 34.83% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $6 respectively. As a result, TRVI is trading at a discount of -53.45% off the target high and -53.45% off the low.
Trevi Therapeutics Inc (TRVI) estimates and forecasts
Statistics show that Trevi Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Trevi Therapeutics Inc (TRVI) shares have gone up 31.65% during the last six months, with a year-to-date growth rate less than the industry average at -68.97% against 16.50.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 27.24%. While earnings are projected to return -67.11% in 2025, the next five years will return -22.64% per annum.
TRVI Dividends
Trevi Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Trevi Therapeutics Inc (NASDAQ:TRVI)’s Major holders
Trevi Therapeutics Inc insiders own 1.04% of total outstanding shares while institutional holders control 70.49%, with the float percentage being 71.23%. NEA MANAGEMENT COMPANY, LLC is the largest shareholder of the company, while 120.0 institutions own stock in it. As of 2024-06-30, the company held over 11.37 million shares (or 11.4255% of all shares), a total value of $33.88 million in shares.
The next largest institutional holding, with 7.38 million shares, is of FRAZIER LIFE SCIENCES MANAGEMENT, L.P.’s that is approximately 7.4169% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $22.0 million.
Also, the Mutual Funds coming in first place with the largest holdings of Trevi Therapeutics Inc (TRVI) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 1.78 shares. This amounts to just over 2.31 percent of the company’s overall shares, with a $6.94 million market value. The same data shows that the other fund manager holds slightly less at 1.4, or about 1.82% of the stock, which is worth about $5.47 million.
